Devices descending from K102668
12 later devices reach Etest Tobramycin 0.016-256 UG/ML and 0.064-1024 UG/ML through their predicates, nearest generation first.
| Generation | Number | Device | Applicant | Decided | Own descendants | Recalls |
|---|---|---|---|---|---|---|
| +1 | K121002 | Etest Ceftaroline | bioMerieux, Inc. | 2012 | 11 | 5 |
| +2 | K151873 | Etest Ceftaroline (0.002 - 32ug/ml) | Biomerieux S.A. | 2015 | 10 | — |
| +3 | K180936 | ETEST Telavancin (TLA) (0.002-32 ug/mL) | Biomerieux S.A. | 2018 | 5 | — |
| +3 | K170670 | Etest Ceftolozane/ Tazobactam (0.016-256 ug/ml) | bioMerieux, Inc. | 2017 | 3 | 1 |
| +4 | K200512 | ETEST Plazomicin (PLZ) (0.016-256 µg/mL) | Biomérieux SA | 2020 | 0 | — |
| +4 | K192738 | ETEST Delafloxacin (DFX) (0.002-32 µg/mL) | Biomerieux S.A. | 2019 | 0 | — |
| +4 | K192050 | ETEST Eravacycline (ERV) (0.002 – 32 µg/mL) | Biomerieux S.A. | 2019 | 2 | 1 |
| +4 | K172150 | Etest Ceftazidime/Avibactam (CZA) (0.016 - 256 ug/mL) | bioMerieux, Inc. | 2017 | 2 | 1 |
| +5 | K250856 | ETEST Aztreonam/Avibactam (AZA) (0.016/4-256/4 µg/mL) | Biomérieux | 2025 | 0 | — |
| +5 | K210757 | ETEST Fosfomycin (FO) (0.032-512 µg/mL) | Biomerieux S.A. | 2021 | 1 | — |
| +5 | K190154 | ETEST Piperacillin/Tazobactam (P/T) (0.016/4-256/4 ug/mL) | Biomerieux S.A. | 2019 | 0 | — |
| +6 | K260447 | ETEST Gepotidacin (GEP) (0.016-256 µg/mL) | bioMérieux SA | 2026 | 0 | — |